ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Integration of geriatric nutritional risk index and sarcopenia for prognostic assessment in nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: a large-scale long-term retrospective study.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNasopharyngeal carcinoma (NPC) is a heterogeneous malignancy with significant variability in survival outcomes among patients receiving concurrent chemoradiotherapy (CCRT), even within the same disease stage. This study aimed to develop and validate a novel prognostic model integrating the geriatric nutritional risk index (GNRI) and sarcopenia to predict overall survival (OS) in NPC patients undergoing CCRT.
methodsWe conducted a large-scale, long-term retrospective analysis of 862 NPC patients treated with CCRT. Pretreatment GNRI and sarcopenia status were assessed, and patients were stratified into cachexia risk groups based on these two factors. Univariate and multivariate Cox regression analyses identified independent prognostic predictors, which were incorporated into a nomogram for individualized OS prediction.
resultsPatients classified as high cachexia risk (low GNRI or presence of sarcopenia) exhibited significantly poorer OS compared to the low cachexia risk group (HR = 0.607, 95% CI: 0.428-0.861, P = 0.005). Multivariate analysis revealed that age > 45 years, advanced T stage, nodal involvement, and high cachexia risk independently predicted worse OS. The nomogram demonstrated favorable discrimination (C-index = 0.715, 95% CI: 0.643-0.787) compared to the traditional tumor-node-metastasis (TNM) staging system (C-index = 0.639, 95% CI: 0.574-0.704).
conclusionsA prognostic model combining GNRI, sarcopenia, and clinicopathological factors effectively stratifies risk in NPC patients receiving CCRT. This integrated approach improves upon conventional staging in predicting OS and supports incorporating comprehensive nutritional and body composition assessments into routine clinical practice to guide personalized treatment strategies.
Indexed as
Identifiers
42760365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.